Concerta 18mg

Clinical Monograph: Concerta 18 mg (Methylphenidate HCl Extended-Release)

1. Classification and Chemical Overview

Methylphenidate hydrochloride is a synthetic piperidine derivative centrally acting sympathomimetic agent. Chemically designated as methyl $\alpha$-phenyl-2-piperidineacetate hydrochloride. Under the Anatomical Therapeutic Chemical (ATC) system, methylphenidate is indexed under N06BA04.

• Product Context: Concerta 18 mg utilizes an advanced OROS (osmotic-controlled release oral system) tablet technology designed to deliver methylphenidate at a controlled rate over a 10- to 12-hour period, mimicking an idealized multi-dose regimen with a single morning administration.

• Controlled Status: Strictly regulated as a Prescription Only Medicine (POM) and a Schedule II Controlled Substance (or Class B / Schedule 2 Controlled Drug internationally) due to its stimulant properties, abuse liability, and psychological dependence potential.

2. Mechanism of Action and Pharmacodynamics

Methylphenidate functions by blocking the reuptake of key monoamine neurotransmitters:

• DAT and NET Inhibition: Binds to dopamine transporters (DAT) and norepinephrine transporters (NET) located on presynaptic neuronal membranes.

• Synaptic Availability Enhancement: Inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations within the synaptic cleft, particularly within the prefrontal cortex and striatum.

• Pharmacodynamic Effect: Enhances executive function, attention regulation, behavioral inhibition, and impulse control in patients with ADHD.

3. Approved Clinical Indications and Dosing Scope

Licensing for Concerta includes:

• Attention Deficit Hyperactivity Disorder (ADHD): Treatment of ADHD in children (aged 6 years and older), adolescents, and adults as part of a comprehensive treatment program.

Dosing & Administration Regimen:

• Morning Administration: Taken orally once daily in the morning with or without food. Avoid late-day dosing to prevent prolonged, severe insomnia.

• Starting Strength: The 18 mg tablet serves as the standard recommended starting dose for patients new to methylphenidate or when transitioning from other stimulant regimens.

• Tablet Integrity: Tablets must be swallowed whole with liquid. Do not chew, crush, divide, or dissolve, as the OROS delivery mechanism relies on a laser-drilled osmotic push-pull design; tampering with tablet integrity causes immediate drug dumping and potential toxicity.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Following oral ingestion, the outer drug coating dissolves to provide an initial immediate-release pulse within 1 to 2 hours. Osmotic pressure then forces active methylphenidate through the laser-drilled membrane at a controlled rate, producing gradually rising plasma concentrations that peak at 6 to 8 hours post-dose.

• Distribution: Rapidly distributes into body tissues. Plasma protein binding is low (~12% to 15%). Crosses the blood-brain barrier.

• Biotransformation: Extensively metabolized in the liver and through non-hepatic pathways primarily by carboxylesterase (specifically CES1A1), converting methylphenidate into its major inactive metabolite, $\alpha$-phenyl-piperidine acetic acid (PPAA).

• Elimination: Excreted predominantly via the kidneys in urine (~90% as PPAA metabolites) and in feces (~1% to 3% as unchanged drug). The terminal elimination half-life averages 3.5 hours, though sustained systemic absorption extends the effective pharmacodynamic duration to roughly 12 hours.

5. Physiological Effects and Adverse Event Spectrum

Concerta stimulates sympathetic outflow, accelerating heart rate, elevating blood pressure, and suppressing appetite.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Decreased appetite, insomnia, headache, upper abdominal pain, nausea, dry mouth.

• Common ($\ge 1/100$ to $<1/10$): Tachycardia, palpitations, anxiety, emotional lability, dizziness, weight loss, restlessness, hyperhidrosis, bruxism, nasopharyngitis, diarrhea.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Hypertension, vision blurred, tremor, rash, pruritus, depressed mood, fatigue, suicidal ideation.

• Rare / Severe (<1/1,000): Psychotic episodes, hallucinations, cerebrovascular accidents, myocardial infarction, sudden cardiac death in vulnerable individuals, priapism, Raynaud’s phenomenon.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contra-indicaties

• Known hypersensitivity to methylphenidate or formulation excipients.

• Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their cessation (risk of severe hypertensive crisis).

• Marked anxiety, tension, or agitation (as stimulants can exacerbate these states).

• Glaucoma, pheochromocytoma, or advanced arteriosclerosis/symptomatic cardiovascular disease.

Key Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent administration triggers severe hypertensive crises and dangerous hyperthermia.

• Antihypertensives & Vasopressors: Stimulants can antagonize the blood pressure-lowering efficacy of antihypertensive drugs and amplify cardiovascular effects of pressor agents.

• Serotonergic Agents: While less common than with amphetamines, concurrent use with potent serotonergic compounds warrants monitoring for serotonin syndrome symptoms.

Clinical Precautions and Monitoring

• Boxed Warning (Abuse, Misuse, and Dependence): CNS stimulants have a high potential for abuse and dependence. Assess clinical risk prior to prescribing and monitor patients regularly for signs of misuse, diversion, or dose escalation.

• Cardiovascular Evaluation & Monitoring: Evaluate baseline cardiac health prior to initiating therapy. Routinely monitor blood pressure and heart rate throughout treatment.

• Gastrointestinal Obstruction Risk: Because the OROS tablet does not change shape in the gastrointestinal tract, use with extreme caution in patients with preexisting severe gastrointestinal narrowing or motility disorders.